Table 4 Univariate and multivariate cox regression analyses

Gender (Male vs. Female)

0.956(0.634–1.441)

0.830

0.821(0.507–1.328)

0.421

Age (< 60 vs. ≥ 60)

0.905(0.595–1.377)

0.642

1.583(0.979–2.559)

0.061

Smoking status

(No vs. Yes)

1.333(0.820–2.165)

0.246

1.472(0.846–2.560)

0.171

ECOG PS (0–1 vs. 2)

2.694(0.974–7.455)

0.056

1.429(0.445–4.590)

0.549

Clinical stage (IIIB/C vs. IV)

1.188(0.682–2.069)

0.543

3.135(1.417–6.935)

0.005

2.640(1.061–6.564)

0.037

Brain metastases (No vs. Yes)

1.892(1.200–2.984)

0.006

2.065(1.305–3.269)

0.002

1.950(1.162–3.270)

0.011

2.136(1.207–3.781)

0.009

Bone metastases (No vs. Yes)

1.100(0.731–1.654)

0.648

1.796(1.106–2.918)

0.018

1.517(0.892–2.580)

0.124

Liver metastases (No vs. Yes)

1.256(0.665–2.372)

0.482

2.171(1.096–4.301)

0.026

1.365(0.666–2.798)

0.396

EGFR 21 L858R mutation

(No vs. Yes)

0.903(0.734–1.111)

0.333

0.774 (0.610–0.982)

0.035

2.221(1.314–3.752)

0.003

TP53 mutation

(Exon8 vs. Other Exons)

0.835(0.490–1.424)

0.509

0.795 (0.431–1.465)

0.462

T790M status at progression

(NA vs. Positive)

0.673(0.445–1.018)

0.061

0.378(0.227–0.631)

P < 0.001

0.294(0.169–0.510)

P < 0.001

Treatment (T vs. TC)

0.465(0.297–0.728)

0.001

0.438(0.279–0.687)

P < 0.001

0.623 (0.364–1.065)

0.084